Category Archives: Global News Feed

SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced they have entered into a research collaboration in 2021. As part of the partnership, Imugene and Celularity will initially collaborate to develop the combination of Imugene’s CD19 oncolytic virus technology and Celularity’s CD19 targeting allogeneic chimeric antigen receptor (CAR) T cellular therapy, CyCART-19, for the treatment of solid tumors. CyCART-19 is a placental-derived T-cell investigational therapy engineered with a CAR that is cryopreserved and will be available off-the-shelf.

The rest is here:
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy...

-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-

Read more:
ObsEva Announces Second Quarter 2021 Financial Results and Business Update

Geneva, Switzerland, August 5, 2021 - Ad Hoc Announcement Pursuant to Art. 53 LR

Original post:
Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update

Saint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was recently awarded Breakthrough Designation status by the Food and Drug Administration (FDA).

Read the rest here:
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate

BASEL, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a dose ranging study of the PDE10A inhibitor NOE-105 in Tourette Syndrome.

Read the original:
Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome

ARESTAT™ formulated product progressing into clinical trial ARESTAT™ formulated product progressing into clinical trial

Link:
Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development...

Company announcement – No. 63 / 2020

The rest is here:
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated...

Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

Go here to see the original:
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

Eliminating one of the convertible notes represents a significant milestone for Global WholeHealth Partners Corp.

Follow this link:
Global WholeHealth Partners Corp (OTC: GWHP) Has Paid Off One of Its Outstanding Convertible Notes

Publication of Supplementary Prospectus

Read more:
Publication of Supplementary Prospectus